+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
siRNA Therapeutics Market by Drug Agent (Givosiran, Inclisiran, Lumasiran), Delivery Systems (Lipid Nanoparticles, Peptide Delivery Systems, Polymer Conjugates), Route of Administration, Therapeutic Categories, End-User - Global Forecast to 2030- Product Image
siRNA Therapeutics Market by Drug Agent (Givosiran, Inclisiran, Lumasiran), Delivery Systems (Lipid Nanoparticles, Peptide Delivery Systems, Polymer Conjugates), Route of Administration, Therapeutic Categories, End-User - Global Forecast to 2030- Product Image
Sale

siRNA Therapeutics Market by Drug Agent (Givosiran, Inclisiran, Lumasiran), Delivery Systems (Lipid Nanoparticles, Peptide Delivery Systems, Polymer Conjugates), Route of Administration, Therapeutic Categories, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6090381
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The siRNA therapeutics market is transforming clinical development with its expanding role in precision medicine and targeted treatments. Senior leaders in pharmaceutical, biotech, and healthcare sectors must understand the current landscape, key growth drivers, and strategic risks to make informed investments and operational decisions.

Market Snapshot: siRNA Therapeutics Market Size & Growth

The siRNA therapeutics market is advancing rapidly, reflecting strong demand for gene silencing solutions that address critical unmet needs. With a solid compound annual growth rate, this sector is seeing dynamic pipeline expansion and adoption by innovators worldwide. Drivers behind this momentum include clinical approvals for novel drug agents, new delivery technologies, and evolving regulatory climates favoring advanced modalities. Emerging delivery systems and improved manufacturing methods further propel accessibility for diverse patient populations and support commercial readiness at scale.

Scope & Segmentation: Comprehensive Coverage of siRNA Therapeutics

This report provides detailed segmentation to offer a nuanced view of the market landscape.

  • Drug Agents: Givosiran, Inclisiran, Lumasiran, Nedosiran, Patisiran, Vutrisiran
  • Delivery Systems: Lipid Nanoparticles, Peptide Delivery Systems, Polymer Conjugates
  • Routes of Administration: Intravenous (IV), Subcutaneous
  • Therapeutic Categories: Cardiovascular disorders, Immunological disorders, Infectious diseases (bacterial and viral), Metabolic disorders, Neurological disorders (Alzheimer’s, Parkinson’s), Oncology (hematologic malignancies and solid tumors)
  • End-User Profiles: Contract Research Organizations, Hospitals & Clinics, Pharmaceutical Companies, Research & Academic Institutes
  • Regional Coverage: Americas (including key U.S. states and leading LATAM countries), Europe, Middle East & Africa (major Western European, Nordic, and Gulf countries), Asia-Pacific (high-growth East Asian, Southeast Asian, and Oceanian markets)
  • Key Companies Analyzed: Leading multinationals and emerging innovators such as Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Moderna Therapeutics, and Silence Therapeutics plc

Key Takeaways for Senior Decision-Makers

  • Recent clinical milestones for small interfering RNA therapies are enabling expansion into more therapeutic areas, with delivery technology advances enhancing targeting and efficacy.
  • Companies are leveraging alliances and licensing agreements to accelerate clinical validation, reduce risk, and access proprietary manufacturing techniques for next-generation drug agents.
  • Adoption of digitalized supply chain management and continuous synthesis methods is improving transparency, yield, and quality standards in siRNA manufacturing workflows.
  • Differences in reimbursement policies and regulatory frameworks across regions require adapted market entry and commercialization strategies, particularly in high-potential jurisdictions such as the U.S., Asia-Pacific, and select EMEA markets.
  • Sustained innovation in delivery platforms and platform modularity supports diversification of R&D portfolios and fosters resilience against shifting regulatory or supply chain conditions.

Impact of 2025 US Tariffs on Supply Chains

New tariff regimes in the United States are reshaping procurement and supplier partnerships for siRNA-related raw materials and delivery substrates. These measures are causing incremental cost pressures, especially for components such as specialty lipids and synthetic oligonucleotides. Developers are responding by exploring alternative sourcing, renegotiating contracts, and considering nearshoring or localized production. Enhanced collaboration with contract research and manufacturing organizations is being deployed to offset potential delays or volatility in supply continuity.

Methodology & Data Sources

This report utilizes a comprehensive methodology, integrating primary interviews with industry leaders and clinical investigators along with secondary research from financials, clinical registries, and trade data. Triangulation of qualitative and quantitative insights ensures validity, while segmentation is grounded in rigorous market mapping and expert validation.

Why This Report Matters

  • Enables pharmaceutical and biotech executives to benchmark strategic priorities against actionable trends in siRNA drug development and commercialization.
  • Supports procurement and R&D leaders in navigating supply chain complexities by providing clarity on regulatory, technological, and market access dynamics across all major regions.
  • Delivers granular competitive analysis and segment-level insights to inform investment, partnership, and expansion strategies.

Conclusion

The siRNA therapeutics market presents actionable opportunities for organizations prioritizing scientific innovation, operational agility, and market alignment. Strategic choices in delivery platforms, partnerships, and regional entry can drive therapeutic and commercial success as the field evolves.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. siRNA Therapeutics Market, by Drug Agent
8.1. Introduction
8.2. Givosiran
8.3. Inclisiran
8.4. Lumasiran
8.5. Nedosiran
8.6. Patisiran
8.7. Vutrisiran
9. siRNA Therapeutics Market, by Delivery Systems
9.1. Introduction
9.2. Lipid Nanoparticles
9.3. Peptide Delivery Systems
9.4. Polymer Conjugates
10. siRNA Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Intravenous (IV)
10.3. Subcutaneous
11. siRNA Therapeutics Market, by Therapeutic Categories
11.1. Introduction
11.2. Cardiovascular Disorders
11.3. Immunological Disorders
11.4. Infectious Diseases
11.4.1. Bacterial Infections
11.4.2. Viral Infections
11.5. Metabolic Disorders
11.6. Neurological Disorders
11.6.1. Alzheimer's Disease
11.6.2. Parkinson's Disease
11.7. Oncology
11.7.1. Hematologic Malignancies
11.7.1.1. Leukemia
11.7.1.2. Lymphoma
11.7.2. Solid Tumors
11.7.2.1. Breast Cancer
11.7.2.2. Lung Cancer
11.7.2.3. Prostate Cancer
12. siRNA Therapeutics Market, by End-User
12.1. Introduction
12.2. Contract Research Organizations
12.3. Hospitals & Clinics
12.4. Pharmaceutical Companies
12.5. Research & Academic Institutes
13. Americas siRNA Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa siRNA Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific siRNA Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alnylam Pharmaceuticals Inc.
16.3.2. Alys Pharmaceuticals Inc.
16.3.3. Arbutus Biopharma Corporation
16.3.4. Arcturus Therapeutics, Inc. by Alcobra Ltd.
16.3.5. Aro Biotherapeutics Co.
16.3.6. Arrowhead Pharmaceuticals Inc.
16.3.7. Atalanta Therapeutics
16.3.8. Biocon Ltd.
16.3.9. e-Therapeutics Plc
16.3.10. Eli Lilly and Company
16.3.11. Ionis Pharmaceuticals Inc.
16.3.12. Merck & Co. Inc.
16.3.13. Moderna Therapeutics
16.3.14. Novartis AG
16.3.15. Novo Nordisk A/S
16.3.16. Phio Pharmaceuticals, Inc.
16.3.17. Quark Pharmaceuticals inc.
16.3.18. Risen Pharma Tech Co Ltd
16.3.19. Roche Holding AG
16.3.20. Shanghai Argo Biopharmaceutical Co., Ltd.
16.3.21. Silence Therapeutics plc
16.3.22. Sirius Therapeutics Inc.
16.3.23. Sirnaomics Inc.
16.3.24. Suzhou Sanegene Bio Inc.
16.3.25. Synerk Inc.
16.3.26. Thermo Fisher Scientific Inc.
16.3.27. Vir Biotechnology, Inc.
16.3.28. Wave Life Sciences USA, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SIRNA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. SIRNA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. SIRNA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SIRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SIRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SIRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY GIVOSIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INCLISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LUMASIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY NEDOSIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY VUTRISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PEPTIDE DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY POLYMER CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 71. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 72. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 74. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 75. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 76. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 77. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 78. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 79. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 81. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 84. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 85. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 87. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 88. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 132. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 135. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 136. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 138. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 139. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 140. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 142. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 145. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 146. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 148. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 149. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 162. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 163. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 165. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 166. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 167. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 168. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 169. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 170. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 172. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 175. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 176. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 177. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 179. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 180. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 212. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 215. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 216. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 217. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 218. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 219. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 220. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 232. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 233. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 235. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 236. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 237. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 238. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 239. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 240. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 242. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 245. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 246. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 248. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 249. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 250. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 272. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 275. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 276. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 277. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 278. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 279. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 280. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 282. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 285. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 286. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 287. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 288. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 289. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 290. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 302. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 305. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 306. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 308. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 309. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 310. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 311. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 312. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 313. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 315. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 316. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 317. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 318. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 319. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 320. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 330. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY THERA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this siRNA Therapeutics market report include:
  • Alnylam Pharmaceuticals Inc.
  • Alys Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics, Inc. by Alcobra Ltd.
  • Aro Biotherapeutics Co.
  • Arrowhead Pharmaceuticals Inc.
  • Atalanta Therapeutics
  • Biocon Ltd.
  • e-Therapeutics Plc
  • Eli Lilly and Company
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Moderna Therapeutics
  • Novartis AG
  • Novo Nordisk A/S
  • Phio Pharmaceuticals, Inc.
  • Quark Pharmaceuticals inc.
  • Risen Pharma Tech Co Ltd
  • Roche Holding AG
  • Shanghai Argo Biopharmaceutical Co., Ltd.
  • Silence Therapeutics plc
  • Sirius Therapeutics Inc.
  • Sirnaomics Inc.
  • Suzhou Sanegene Bio Inc.
  • Synerk Inc.
  • Thermo Fisher Scientific Inc.
  • Vir Biotechnology, Inc.
  • Wave Life Sciences USA, Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.25 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.33 Billion
Compound Annual Growth Rate10.3%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Small Nucleic Acid Therapies Market by Therapy Type (Antisense Oligonucleotides, Aptamers, miRNA Therapeutics), Route of Administration (Oral Route, Parenteral Route), Delivery Mechanism, Therapeutic Application, End User - Global Forecast 2025-2030 - Product Image

Small Nucleic Acid Therapies Market by Therapy Type (Antisense Oligonucleotides, Aptamers, miRNA Therapeutics), Route of Administration (Oral Route, Parenteral Route), Delivery Mechanism, Therapeutic Application, End User - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
2024 DNA and RNA Synthesis Research Review - Product Image

2024 DNA and RNA Synthesis Research Review

  • Report
  • 184 Pages
  • Global
From
Cell Penetrating Peptides - Global Strategic Business Report - Product Image

Cell Penetrating Peptides - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Glow Cell Assay Reagents Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Glow Cell Assay Reagents Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Antibody-oligonucleotide Conjugates Market by Oligonucleotide Type, Conjugation Methodology, Targeting Strategy, Application, End-User - Global Forecast 2025-2030 - Product Image

Antibody-oligonucleotide Conjugates Market by Oligonucleotide Type, Conjugation Methodology, Targeting Strategy, Application, End-User - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.